Table 1.
Baseline characteristics
| Sofosbuvir/daclatasvir (N = 541) | Control (N = 542) | |
|---|---|---|
| Baseline demographics | ||
| age (years), median (IQR) | 57 (45–69) | 59 (46–69) |
| sex (female), n (%) | 250 (46) | 248 (46) |
| BMI (kg/m2), median (IQR) | 27 (24–31) | 27 (24–30) |
| Vitals on admission, median (IQR) | ||
| oxygen saturation (%) | 90 (88–93) | 90 (87–93) |
| respiratory rate (breaths/min) | 20 (18–23) | 20 (18–23) |
| temperature (°C) | 37 (36.7–37.5) | 37 (36.8–37.5) |
| Comorbidities, n (%) | ||
| hypertension | 187 (35) | 181 (34) |
| diabetes | 153 (28) | 146 (27) |
| ischaemic heart disease | 53 (10) | 46 (8) |
| asthma | 28 (5) | 24 (4) |
| COPD | 9 (2) | 14 (3) |
| COVID-19 diagnosis | ||
| PCR positive, n (%) | 430 (79) | 426 (79) |
| CT lung involvement percentage categories, n (%)a | ||
| 0–25 | 94 (17) | 85 (16) |
| 26–50 | 267 (49) | 293 (54) |
| 51–75 | 138 (26) | 123 (23) |
| 76–100 | 42 (8) | 41 (8) |
| days since symptom onset, median (IQR)b | 8 (6–10) | 8 (6–10) |
| Laboratory findings, median (IQR) | ||
| white blood cells (/μL) | 5900 (4500–8400) | 5900 (4400–8640) |
| neutrophils (%) | 75 (67–83) | 74 (65–82) |
| lymphocytes (%) | 18 (11.5–25.2) | 19 (12.4–26.0) |
| absolute lymphocyte count (/μL) | 1013 (740–1425) | 1068 (767–1412) |
| c-reactive protein (mg/L) | 36 (20–63) | 36 (20–62) |
| Oxygenation status, n (%)c | ||
| room air | 397 (73) | 408 (75) |
| nasal oxygen | 143 (26) | 133 (25) |
| intubated | 1 (0.2) | 1 (0.2) |
Baseline characteristics were obtained at screening unless otherwise stated.
a
All individuals had CT involvement.
b
Reported is the day to randomization since first symptoms.
c
Oxygen status reported was that at randomization. No individuals were intubated at hospital admission as per the eligibility criteria.